Browse Drug Recalls
1,018 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,018 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,018 FDA drug recalls in NY.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Nov 12, 2021 | EPINEPHIrine in 0.9% Sodium Chloride Injection, 4 mg per 250 mL (16 mcg per m... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | dilTIAZem HCl in 5% Dextrose Injection, 125 mg per 125 mL, (32 mcg per mL), R... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | EPINEPHrine, 2 mg per 250 mL (8 mcg per mL) in 0.9% Sodium Chloride Injection... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | EPINEPHrine in 0.9% Sodium Chloride Injection, 16 mg per 250 mL (64 mcg per m... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | EPINEPHIrine in 0.9% Sodium Chloride Injection, 8 mg per 250 mL (32 mcg per m... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Fentanyl Citrate, in 0.9% Sodium Chloride Injection, 2.5 mg per 250 mL, (10 m... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | NOREPINEPHRINE 4 mg per 250 mL (16 mcg per mL) in 5% Dextrose Injection, Rx o... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | PHENYLepherine HCL in 0.9% Sodium Chloride, 20 mg per 250 mL (80 mcg per mL),... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Sodium Bicarbonate in 5% Dextrose Injection, Rx Only, SterRx, 141 Idaho Ave.,... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | NOREPINEPHRINE, 4 mg per 250 mL, (18 mcg per mL) in 0.9% Sodium Chloride Inje... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Midazolam in 0.9% Sodium Chloride Injection, 100 mg per 100 mL (1 mg per mL),... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | dilTIAZem HCl 125 mg per 125 mL (1 mg per mL) in 0.7% Sodium Chloride Injecti... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Morphine Sulfate in 5% Dextrose Injection, 100 mg per 100 mL (1 mg per mL), R... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Midazolam in 0.9% Sodium Chloride Injection, 50 mg per 50 mL (1 mg per mL), R... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Sodium Bicarbonate in 5% Dextrose Injection, 150 mEq per 1000 mL (12.6 mg per... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Succinylcholine Chloride Injection, 200 mg per 10 mL (20 mg per mL), 1,000 mL... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | PHENYLephrine HCl, 40 mg per 250 mL, (160 mcg per mL) in 0.9% Sodium Chloride... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | Fentanyl Citrate, in 0.9% Sodium Chloride Injection, 1 mg per 100 mL, (10 mcg... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | NOREPINEPHRINE, 8 mg per 250 mL, (32 mcg per mL) in 0.9% Sodium Chloride Inje... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | NOREPINEPHRINE, 16 mg per 250 mL, (64 mcg per mL) in 0.9% Sodium Chloride Inj... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | NOREPINEPHRINE, 16 mg per 250 mL, (64 mcg per mL) in 5% Dextrose Injection, R... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 12, 2021 | MORPHINE SULFATE, in 0.9% Sodium Chloride Injection, 50 mg per 50 mL, (1 mg p... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Nov 4, 2021 | Flocinolone Acetonide 0.01% Topical Oil, Scalp Oil, Rx, packaged in 4 oz. bot... | Subpotent Drug: Out-of-specification assay result was obtained for Fluocinolone Acetonide. | Class II | Amneal Pharmaceuticals of New York, LLC |
| Nov 4, 2021 | Flocinolone Acetonide 0.01% Topical Oil, Body Oil, Rx, packaged in 4 oz. bott... | Subpotent Drug: Out-of-specification assay result was obtained for Fluocinolone Acetonide. | Class II | Amneal Pharmaceuticals of New York, LLC |
| Oct 13, 2021 | PainAway II (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) tablets , 2 ... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | Xpect First aid Extra Strength PAIN AWAY (Acetaminophen 250 mg/Aspirin 250 mg... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | North by Honeywell PAIN STOPPER EXTRA STRENGTH (Acetaminophen 250 mg, Aspirin... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | AERO Tab PAIN RELIEVER (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) t... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | ZEE+ painaid ESF Extra-Strength Formula (Acetaminophen 250 mg, Aspirin 250 mg... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | Vica-Cet BACK PAIN RELIEF (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | Afassco Pain Free Plus X-STRENGTH PAIN RELIEVER (Acetaminophen 250 mg/Aspirin... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Oct 13, 2021 | Advance Formula Pain Reliever (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 6... | Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compou... | Class III | Ultra Seal Corporation |
| Aug 13, 2021 | Chantix (varenicline) tablets 1 mg, 56 Tablets, Rx only, Distributed by Pfiz... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim ac... | Class II | Pfizer Inc. |
| Aug 13, 2021 | Chantix (varenicline) tablets 0.5mg/1mg, 56 Tablets, Rx only, Distributed by... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim ac... | Class II | Pfizer Inc. |
| Aug 13, 2021 | Chantix (varenicline) tablets 1 mg, Carton containing 4 blister packs of 14 t... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim ac... | Class II | Pfizer Inc. |
| Aug 13, 2021 | Chantix (varenicline) tablets 0.5mg, 56 Tablets, Rx only, Distributed by Pfi... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim ac... | Class II | Pfizer Inc. |
| Aug 10, 2021 | Sodium Bicarbonate in 5% Dextrose Injection, 150 mEq per 1,000 mL (12.6 mg pe... | Lack of Assurance of Sterility | Class II | SterRx, LLC |
| Aug 10, 2021 | Sodium Bicarbonate in 5% Dextrose Injection, 150 mEq per 1,000 mL (12.6 mg pe... | Non-Sterility: firm's third party lab confirmed microbial contamination. | Class I | SterRx, LLC |
| Jul 7, 2021 | Acetaminophen EXTRA STRENGTH Pain Reliever / Fever Reducer, Enteric Coated, 5... | Labeling: Not Elsewhere Classified The primary label contains the words "enteric coated" but the ... | Class III | LNK International, Inc. |
| Jun 16, 2021 | Acetaminophen 325 mg tablets, Regular Strength Pain Reliever, 100-count bottl... | cGMP deviations: Discolored acetaminophen | Class II | Spirit Pharmaceuticals |
| Jun 9, 2021 | Chantix (varenicline)Tablets, Contains: 1 Starting Week (0.5 mg* x 11 tablets... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acc... | Class II | Pfizer Inc. |
| Jun 9, 2021 | Chantix (varenicline) tablets, 1 mg, 56 Tablets, Rx Only, Distributed by Pfiz... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acc... | Class II | Pfizer Inc. |
| Jun 9, 2021 | Chantix (varenicline) tablets, 0.5mg*, 56 Tablets, Rx Only, Distributed by Pf... | CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim ac... | Class II | Pfizer Inc. |
| May 3, 2021 | Sterile Water for Inj., USP, 25 x 100 mL Single Dose Vials per carton, Rx onl... | Presence of Particulate Matter: particulate matter identified as an insect in one vial. | Class II | Pfizer Inc. |
| Apr 8, 2021 | Premium OrgaZEN 7000 capsule, 1-count per blister card, distributed by: Nutra... | Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/ or ta... | Class I | NSNY Distributor Inc |
| Apr 8, 2021 | Ginseng Power 5000 capsule, 1- count per blister card, GS Natural Co, Los Ang... | Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/ or ta... | Class I | NSNY Distributor Inc |
| Mar 19, 2021 | Neomycin Sulfate Tablets, USP 500mg, Rx Only, 10x10 Unit dose 100 Tablets, M... | Failed Stability Specifications: Out of Specification (OOS) result reported for microbiological ... | Class II | X-Gen Pharmaceuticals Inc. |
| Jan 8, 2021 | Nortriptyline HCl Capsules, USP equivalent to 10mg base Mfd. by: Taro Pharmac... | CGMP deviations. | Class II | Taro Pharmaceuticals U.S.A., Inc. |
| Nov 17, 2020 | H-E-B - Athlete's Foot Cream Clotrimazole Cream USP, 1% Anitfungal NET WT. 0.... | Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slight... | Class II | Taro Pharmaceuticals U.S.A., Inc. |
| Nov 17, 2020 | Equate Athlete's Foot, Clotrimazole USP 1%, Antifungal Cream, Packaged as a) ... | Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slight... | Class II | Taro Pharmaceuticals U.S.A., Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.